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Abstract 
Syphilis is a sexually transmitted infection that, if left untreated, can impact fetal development. In this 
systematic review of syphilis in pregnancy, we attempt to better understand worldwide discrepancies 
regarding its diagnosis and management. OVID MEDLINE and PubMed databases were searched for 
keywords and 74 relevant articles were identified. Twenty-nine articles were ultimately included in our 
review. In the literature spanning from 1944—2014, we identified several variations in maternal syphilis 
screening and treatment, as well as a spectrum of gestational outcomes. Even following the publication 
of universal guidelines by the World Health Organization, the Centers for Disease Control and 
Prevention, and scientific investigators, practice patterns have continued to vary. Greater adherence to 
these guidelines could improve the quality of research in this area and promote earlier detection and 
thus prevention of maternal and congenital syphilis. 
Introduction 
Syphilis is caused by infection with a spirochete, 
Treponema pallidum, which can be passed to the 
mother during sexual contact and subsequently 
from mother to child during pregnancy. ,  1 2
Untreated syphilis can progress through multiple 
stages (Table 1) and can be characterized by 
painless papules in the mouth, genitals, rectum, 
or skin, body rash, headache, fever, fatigue, and 
lymphadenopathy.  Progression to tertiary 3
syphilis can result in damage to the heart, eyes, 
brain, and nervous system.1
Patients can also have latent syphilis with a 
positive serological test and no clinical signs of 
syphilis.1,3 Early latent syphilis typically manifests 
one year after infection. Late latent syphilis is 
clinically described as an infection of unknown 
duration. Although T. pallidum cannot be 
transmitted sexually in late latent stage syphilis, 
pregnant women can transmit the treponeme to 
their fetuses.1,2,3
In 2008, more than 1 million pregnant women 
worldwide were newly infected with syphilis,[4] 
and it is estimated that 12 million new infections 
occur each year.3 Syphilis in pregnancy results in 
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many complications, the most deadly of which is 
congenital syphilis. Newman et al. estimate that 
520,000 adverse outcomes occurred in 2008 as 
a result of maternal syphilis infection.  Due to 4
these adverse outcomes, the World Health 
Organization (WHO) recommends that all 
pregnant women be tested for syphilis early in 
antenatal care (ANC) and begin treatment if 
i n fec ted . [2Wor ld Hea l th Organ iza t ion , 
Department of Reproductive Health and 
Research. The global elimination of congenital 
syphilis: rationale and strategy for action. 
Geneva, Switerland: WHO Press; 2007.] The 
Centers for Disease Control and Prevention 
(CDC) and WHO both recommend maternal 
penicillin therapy (Table 2); although, in practice, 
there is considerable therapeutic heterogeneity.
Maternal syphilis infections are preventable and 
treatable. However, the global burden of this 
disease in pregnancy persists. The broad 
variation in the diagnosis and management of 
maternal syphilis could be a contributing factor.  5
In this review, we discuss variations in the 
delivery of antenatal care, treatment of maternal 
syphilis, and diagnosis of congenital syphilis in 
an effort to better understand these variations 
and potential avenues for achieving greater 
therapeutic homogeneity.
Search Strategy and Selection Criteria
A systematic search of peer-reviewed published 
articles was performed using OVID MEDLINE. 
The MeSH terms applied were “Syphilis, 
Congenital”, “Pregnancy Complications” and 
“Pregnancy Outcome” in combination. Search 
results were limited to English language studies 
using human subjects published through June 
2014 to identify the most up-to-date information 
regarding worldwide clinical practice. This search 
yielded seventy-four articles, which were 
reviewed by a subset of the authors. Five more 
articles were reviewed by suggestion of the 
senior author. Twenty-nine were selected for 
further review and were grouped together based 
on their emphasis of syphilis screening practices, 
treatment, and gestational outcomes.
Prenatal Screening 
Antenatal Care
Syphilis screening in conjunction with antenatal 
care (ANC) is strongly recommended by the 
WHO and CDC. While it is estimated that each 
year 2 million  pregnant women are infected with 
syphilis, only 85% of pregnant women worldwide 
access antenatal care at least once. Even fewer, 
58%, have access to four or more visits with an 
ANC provider. ,  Of the women who receive 6 7
ANC, only two thirds are tested for syphilis.  8
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Even if ANC is sought, earlier screening, and 
thus earlier treatment, has the greatest impact 
on maternal and fetal health.  Hawkes et al.  9 10
found that an infant born to a mother who was 
not screened early in pregnancy is nearly three 
times as likely to present evidence of infection. 
Furthermore, screening and treatment during 
late pregnancy does not reliably reduce fetal 
transmission rates since the intervention period 
is shorter and the likelihood of fetal transmission 
is increased.11
Screening Tests
Screening tests for syphilis are categorized as 
non-treponemal or t reponemal. A non-
treponemal test indirectly identifies infected 
individuals by detecting the presence of non-
specific IgG or IgM antibodies, which are 
elevated in syphilis.  These antibodies are 12
present as a result of either direct production 
from treponemes or as debris from cellular 
damage of host cells.12 The first mass-produced, 
non-treponemal test was the Venereal Disease 
Research Laboratory (VDRL) (Table 3). Other 
non-treponemal tests include Rapid Plasma 
Reagin (RPR) and Toluidine Red Unheated 
Serum Test (TRUST).12 Despite their high 
sensitivities (86% and 85%, respectively), these 
screening tools are prone to false positives 
because they are not specific to T. pallidum.  13
Contrary to non-treponemal tests, treponemal 
tests directly identify the presence of T. pallidum. 
The most common tests include the Fluorescent 
Treponemal Antibody-Absorption test (FTA-
ABS), the Serodia Treponema Pallidum Passive 
Particle Agglutination test (TP-PA) and the 
Treponema Pallidum Hemagglutination Assay 
(TPHA). A recent development in treponemal 
testing is the immunochromatographic strip (ICS) 
test, in which a test strip indicates the presence 
of treponemal antibodies. Tucker  found that 14
ICS is rapid, simple to perform, and boasts a 
high specificity (99%).
Point-of-care (POC) tests may more effectively 
address syphilis infections because diagnosis 
and prompt treatment can prevent vertical 
transmission. Rapid diagnosis also presents an 
opportunity to engage women in conversations 
regarding sexual behavior and minimizes loss to 
follow-up.   Still, barriers exist with some tests, 
such as availability in rural areas and reduced 
accuracy which disproportionately impacts 
pregnant women specifically in areas such as 
Sub-Saharan Africa and South Asia where less 
than 50% of women receive antenatal care.1516
Recent technological advances have given rise 
to new treponemal tests. Rapid POC tests 
typically require blood from a fingerstick, a 
procedure that can be performed with minimal 
training in a resource-limited setting. In the 
United States only one POC test, Trinity Health 
CheckTM (Diagnostics Direct, LLC, Stone 
Harbor, NJ), is FDA-cleared.
The “traditional” testing algorithm has been to 
first administer a non-treponemal test, with a 
confirmatory treponemal test in the case of a 
positive.  However, this algorithm poses some 17
challenges. The stage of disease often affects 
the sensitivity of both non-treponemal and 
treponemal tests. According to Peterman et al. ,18
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15% of individuals with latent syphilis could have 
negat ive non- t reponemal tes t resu l ts . 
Additionally, the high rate of positive results from 
treponemal tests underscores the fact that 
previous infections can cause positive test 
results potentially for years following successful 
treatment. For this reason, treponemal tests are 
not appropriate indicators for measuring 
treatment success.17, 18
The CDC now recommends a reverse sequence 
algorithm to detect infections that might 
otherwise be missed by the traditional screening 
method.  The reverse sequence utilizes a 19
treponemal test and, if positive, is followed by a 
quantitative non-treponemal test. In cases of 
negative treponemal tests, an RPR is repeated 
several weeks later for patients considered at 
risk for syphilis. Advantages of switching to the 
reverse algorithm include high throughput, cost 
savings in high volume settings, and the 
detection of chronic, untreated syphilis.  20
However, it is possible that reverse sequence 
screening will produce a higher rate of false 
positives due to the lower sensitivity of some 
treponemal tests. Future studies could further 
investigate this caveat.
Testing Implementation
Despite the wide variety of tests, cost is still the 
prevailing factor determining worldwide use. 
Because treponemal tests generally require 
expensive laboratory equipment and materials, 
they are often difficult to perform in resource-
poor areas where infection rates are usually the 
highest.17 Even though the reverse algorithm is 
now recommended, this has only shown to be 
economically beneficial in developed nations; the 
opposite may hold true in developing countries.20 
For example, Wiwanitkit  found that treponemal 21
screening in blood centers in Thailand would 
cost 2-2.5 times that of non-treponemal 
screening, and Binnicker et al.  found that in the 22
U.S., costs for six different treponemal tests 
range from $1.73 to $18.75 compared to $0.51 
for an RPR test. Thus, in a resource-limited 
setting, rapid and POC syphilis tests may be the 
most efficient and cost-effective option.
Though widely-recognized guidelines for 
screening have been in place since 1988, in 
practice there is great variability in antenatal 
screening for maternal syphilis . We found 23
screening protocols ranging from 1) RPR and 
FTA-ABS , 2) RPR and TP-PA , 3) RPR and 24 25
ICS17, 4) RPR and either FTA-ABS or TP-PA , 26
5) VDRL and FTA-ABS , and 6) TRUST and TP-27
PA confirmed with FTA-ABS.11   Overall, a 
multitude of factors, such as cost, setting, and 
disease stage at presentation likely impact 
whether prenatal screening can be carried out 
according to guidelines.
Treatment of Maternal Syphilis 
Current Recommendations
The CDC’s 2015 Sexually Transmitted Diseases 
Treatment Guidelines specify that only parenteral 
penicillin G (PCN) has documented efficacy for 
syphilis in pregnancy and should be used to 
prevent maternal-fetal transmission (Table 2).19 
Before benzathine PCN was widely used, 
fetuses of mothers with syphilis had a 70% risk 
of contracting congenital syphilis.  After its 28
widespread use, treatment of maternal syphilis 
prevented 98% of congenital infections.  Today, 29
the CDC guidelines outline a specific treatment 
regimen appropriate for a patient’s stage of 
infection (Table 2). The WHO has similar 
guidelines and also recommends treatment of all 
sero-reactive pregnant women with benzathine 
PCN therapy.  However, until recently, the WHO 30
had only specified a single dose of benzathine 
PCN and did not provide treatment regimens 
according to disease stage. In the face of 
antibiotic resistance and in effort to update 
national guidelines for the treatment of syphilis, 
the WHO released new recommendations for the 
first time in over a decade which now correspond 
with the CDC’s treatment of primary, secondary, 
and latent syphilis. Interestingly, though, these 
new gu ide l i nes i nc lude a cond i t i ona l 
recommendation that ceftriaxone or macrolides 
may be used as an alternative treatment for 
pregnant women allergic to PCN when 
desensitization is not possible or unavailable, 
w h i c h i s i n c o n t r a s t t o t h e C D C ’ s 
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recommendat ions which firmly suppor t 
desensitization alone.
Treatment of syphilis in pregnancy should be 
completed at least 30 days before delivery in 
order to avoid increased risk of adverse 
outcomes associated with late treatment.12 
Cheng et al.11 found that treatment close to the 
delivery date is less effective in reducing risk for 
congenital syphilis because the intervention time 
period is shorter compared to normal treatment 
courses. Women who have their first serological 
screening test for syphilis at 28 weeks gestation 
or later are nearly twice as likely to deliver an 
infant with congenital syphilis as those whose 
first test occurred earlier9. The risk of vertical 
transmission from an infected mother is reduced 
with treatment at earlier stages of pregnancy.11 
Regardless of timing, treatment at any stage 
reduces the risk of transmission.
Variations in Treatment Timeline
Within the literature, there are notable variations 
from the aforementioned CDC/WHO treatment 
guidelines. The primary of these concerns 
benzathine PCN dosage schedules that may 
have differed from the recommended guidelines. 
While both guidelines, until recently, suggested 
different dosages per stage of the disease, it is 
unclear from the studies that were reviewed if 
that is what dictated treatment plans in practice. 
Many studies did not report the exact dosage of 
benzathine PCN used, but stated that CDC/
WHO guidelines were followed. Others did not 
record or report the disease stage of their 
subjects. For example, Owusu-Edusei et al.17 
treated every subject with a single dose of 2.4 
MU of PCN and thus may have undertreated 
pregnant women with late latent syphilis. Casal 
et al.  took disease stage into consideration, but 31
perhaps over-treated women with early latent 
syphilis. Uniform adherence to CDC/WHO 
treatment guidelines in both developed and 
resource-poor regions may substantially 
minimize these discrepancies.
Alternative Therapies
Although PCN therapy is the most effective 
t reatment , some studies in Asia have 
documented use of other antibiotics. In a 
prospective study conducted by Sangtawesin et 
al. , erythromycin was used to treat maternal 32
syphilis in approximately 15% of cases. The 
authors did not provide a clear rationale for the 
clinical use of erythromycin; however, concluded 
that it is probably adequate for treating maternal 
syphilis but not in utero syphilis. Similarly, Cheng 
et al.11 reported use of both erythromycin and 
azithromycin for seropositive pregnant women 
allergic to PCN, differing starkly from the CDC 
guidelines. Interestingly, the study did find a 
99.1% success rate in preventing maternal-to-
fetal transmission. Although the authors note that 
diagnosis and management followed CDC 
Guidelines for Prevention and Control of 
Congenital Syphilis, it is unclear which criteria 
dictated the use of alternative antibiotics. Further 
exploration is necessary to assess both the 
context for alternative therapies and the degree 




Syphilis in pregnancy increases the risk of 
adverse outcomes, including pre-term delivery, 
low birth weight, non-immune hydrops fetalis, 
intrauterine growth restriction, stillbirth, and 
congenital syphilis.26, , . While 20% of infants 33 34
born to untreated mothers are without any 
adverse outcomes, the chance of having an 
infant with global delay (40%), stillbirth (30%), 
and neonatal death (40%) is significantly higher 
for untreated versus treated mothers.34 Watson-
Jones et al.  also found that women with high-35
titer active syphilis had an 18-fold increased risk 
of stillbirth and a 4-fold increased risk of any 
adverse outcomes to the infant. The study also 
found that women treated for high- and low-titer 
active syphilis experienced no increased risk in 
adverse outcome compared with women who 
were seronegative for syphilis.
Women who do not receive ANC have 
consistently given birth to the highest proportion 
of infants with congenital syphilis.9, 11 In China, 
infected mothers who never underwent prenatal 
examinations and only received care during 
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delivery contributed the largest share (63%) of 
infants born with congenital syphilis.11 In Russia, 
a study by Tikhonova et al.9 found that among 
women without ANC, 86% delivered an infant 
with congenital syphilis. Jones et al.  found that 36
four out of five cases of congenital syphilis were 
associated with mothers who did not receive 
ANC.
While the gestational outcomes of syphilis have 
b e e n w e l l d e s c r i b e d , t h e s p e c i fi c 
pathophysiologic changes occurring in utero 
have not been clearly elucidated. It is unclear 
whether these adverse outcomes are attributable 
to maternal syphilis, congenital syphilis, or both. 
It remains unclear whether these outcomes are 
due to maternal infection resulting in a less 
favorable intra-uterine environment for the 
developing fetus or whether these outcomes are 
the result of fetal transmission and subsequent 
pathogenicity.
Definitions of Congenital Syphilis
A complete standardization of diagnostic criteria 
for congenital syphilis remains to be established. 
Based on the number of screening test options 
alone, there are at least 21 different ways to 
diagnose congenital syphilis.  Kaufman et al.37 37
were the first to organize specific criteria, 
classifying several cases of congenital syphilis 
as “definite”, “probable”, or “unlikely”. In 1988, 
the CDC established a new set of diagnostic 
criteria, expanding the classifications to 
“confirmed”, “compatible” or “probable,” and 
“unlikely”. In addition, contrary to the CDC 
recommendations, Kaufman et al.37 suggest a 
variety of non-treponemal and treponemal tests 
to confirm a diagnosis. These substantial 
differences represent the significant variation 
that exists among the prevailing classification 
systems worldwide.
Still, investigators continue to utilize variable 
diagnostic criteria. For example, Southwick et al.
24  focused on laboratory results and considered 
a case of congenital syphilis to be laboratory-
confirmed if the infant was born to a seropositive 
mother and had either a positive direct 
fluorescent antibody test, immunohistochemistry 
test, or IgM western blot assay. However, even 
these authors acknowledge possible sources of 
variation in their own testing because either 
whole spirochetes or bacterial fragments could 
constitute a positive result. Other groups have 
made diagnoses based on criteria that covered a 
wider range of tests.  In Russia, as cited by 38
Tikhonova et al., infants must be symptomatic, 
have persistent serological abnormalities, or be 
diagnosed with syphilitic stillbirth in order to be 
reported as a case of congenital syphilis.9 
Furthermore, while WHO criteria define “syphilitic 
stillbirth” as fetal death after 20 weeks, the 
Russian Federation requires a gestational age of 
at least 28 weeks.9 These two requirements 
therefore likely underestimate the prevalence of 
congenital syphilis in the Russian Federation. 
Physical diagnosis can also be difficult as clinical 
manifestations may not be present at birth , and 39
even if there are signs in symptomatic infants, 
they may be subtle and nonspecific, making 
diagnosis difficult.12 Overall, variations in 
outcomes based on different diagnostic criteria 
could justify a need for universal criteria.
 
Discussion 
While syphilis is preventable and curable, it 
continues to be a worldwide public health 
concern , espec ia l l y among women o f 
reproductive age. Through our review, we found 
significant worldwide variation in maternal and 
congenital syphilis diagnosis and treatment. 
Specifically, we observed continued deviation 
from the CDC/WHO’s recommended guidelines 
many years after they were first published. 
Aligning practice with recommended guidelines 
could significantly improve maternal health and 
fetal outcomes. Timely ANC interventions, as 
previously discussed, are a critical element 
underlying initiatives to reduce syphilis in 
pregnancy.
Unfortunately, many women do not receive ANC 
or are not screened for syphilis.4, 8, 10 Often, if 
ANC is pursued, it is at a stage too late for 
effective treatment or prevention. Low rates of 
ANC may be due in part to the cost of screening 
and diagnost ic tests. Whi le automated 
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treponemal tests are preferable for their high 
throughput and automated process, these 
methods are more expensive and less realistic 
for application in resource-poor areas. In these 
areas, syphilis rapid and point-of-care tests are 
likely the most pragmatic option for diagnosis.
Challenges remain if untreated maternal syphilis 
gives rise to congenital syphilis. The range of 
definitions and diagnostic criteria for congenital 
syphilis greatly impacts the delivery of timely and 
successful treatment. Even though many 
standardized criteria have been put forth, the 
literature indicates that these are only partially 
followed. Given the often understated and 
diverse constellation of symptoms in neonates, it 
is imperative to follow established criteria in 
order to accurately diagnose more cases of 
congenital syphilis. As a result, standardized 
diagnostic criteria could better estimate the true 
prevalence of congenital syphilis. Hence, a 
consensus on diagnostic criteria for congenital 
syphilis should be considered.
Our review is subject to some limitations. While 
the OVID MEDLINE and PubMed databases 
were searched to maximize a variety of results, 
other sources outside of the journal articles in 
the databases could be explored. Unpublished 
t r i a l s , c o n f e r e n c e p r o c e e d i n g s , a n d 
manufacturers’ reports could be potentially 
valuable sources, and experts and primary 
authors from primary studies could be contacted 
for additional relevant information. As for the 
extent of the review, an even more thorough 
rev iew of the l i te ra ture could inc lude 
investigation into clinical differences in patient 
selection or characteristics, conditions of 
measurements, and covariate variables.
Reducing maternal and congenital syphilis is a 
global priority. By bringing attention to variations 
in global practices concerning maternal syphilis 
infection, we hope to promote action towards a 
more standardized, financially feasible, and 
socially adaptable model of screening and 
treatment.
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